clonazepam has been researched along with Phobic Disorders in 41 studies
Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.
clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.
Phobic Disorders: Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clonazepam, a high-potency benzodiazepine marketed for the treatment of minor motor epilepsy, was used to treat 50 patients with panic disorder (N = 22) or agoraphobia with panic attacks (N = 28)." | 7.67 | Treatment of panic disorder and agoraphobia with clonazepam. ( Rosenbaum, JF; Spier, SA; Tesar, GE; Woods, SW, 1986) |
| "Fifty patients with panic disorder or agoraphobia with panic attacks with treated with clonazepam, a high potency benzodiazepine." | 7.67 | Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. ( Pollack, MH; Rosenbaum, JF; Spier, SA; Tesar, GE, 1986) |
| "Four patients with panic disorder whose panic attacks responded to benzodiazepine treatment but who suffered persistent anxiety improved after addition of buspirone." | 3.67 | Adjunctive buspirone in benzodiazepine treatment of four patients with panic disorder. ( Gastfriend, DR; Rosenbaum, JF, 1989) |
| "Clonazepam, a high-potency benzodiazepine marketed for the treatment of minor motor epilepsy, was used to treat 50 patients with panic disorder (N = 22) or agoraphobia with panic attacks (N = 28)." | 3.67 | Treatment of panic disorder and agoraphobia with clonazepam. ( Rosenbaum, JF; Spier, SA; Tesar, GE; Woods, SW, 1986) |
| "Fifty patients with panic disorder or agoraphobia with panic attacks with treated with clonazepam, a high potency benzodiazepine." | 3.67 | Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. ( Pollack, MH; Rosenbaum, JF; Spier, SA; Tesar, GE, 1986) |
| "Add-on effect of Shirodhara reduced the daytime sleepiness." | 2.77 | Clinical efficacy of Manasamitra Vataka (an Ayurveda medication) on generalized anxiety disorder with comorbid generalized social phobia: a randomized controlled study. ( Chandrashekar, CR; Kutty, BM; Lavekar, GS; Prabha, TN; Sudhakar, D; Tubaki, BR, 2012) |
| "Benzodiazepine withdrawal symptoms were also measured." | 2.69 | Discontinuation of clonazepam in the treatment of social phobia. ( Book, SW; Colket, JT; Connor, KM; Davidson, JR; Ferrell, F; Malik, ML; Miner, CM; Potts, NL; Tupler, LA, 1998) |
| "Clonazepam and placebo were administered in a double-blind pilot study to 75 outpatients with social phobia." | 2.67 | Treatment of social phobia with clonazepam and placebo. ( Davidson, JR; Ford, SM; Krishnan, R; Potts, N; Richichi, E; Smith, R; Wilson, WH, 1993) |
| "Clonazepam was found to have a significant effect on the treated patients, as demonstrated by scores on a variety of instruments measuring overall anxiety and phobic avoidance, and social phobic symptoms." | 2.67 | Clonazepam in the treatment of social phobia: a pilot study. ( Appleton, AA; Baltazar, PL; Bohn, PB; Cabe, DD; Munjack, DJ, 1990) |
| " Finally, the authors discuss general issues concerning the relapse of patients upon drug discontinuation, the long-term use of benzodiazepines, and other important issues concerning the use of these agents for the treatment of social phobia." | 2.39 | Treatment of social phobia with benzodiazepines. ( Davidson, JR; Potts, NL; Tupler, LA, 1994) |
| "Excessive sweating (hyperhidrosis) is an overlooked and potentially disabling symptom, which is often seen in social anxiety disorder (SAD)." | 1.31 | Hyperhidrosis in social anxiety disorder. ( Churchill, LE; Connor, KM; Davidson, JR; Foa, EB, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (17.07) | 18.7374 |
| 1990's | 18 (43.90) | 18.2507 |
| 2000's | 8 (19.51) | 29.6817 |
| 2010's | 7 (17.07) | 24.3611 |
| 2020's | 1 (2.44) | 2.80 |
| Authors | Studies |
|---|---|
| Lohiya, N | 2 |
| Karve, S | 1 |
| Agarkhedkar, S | 1 |
| Roy-Byrne, P | 1 |
| Pollack, MH | 7 |
| Van Ameringen, M | 2 |
| Simon, NM | 1 |
| Worthington, JW | 1 |
| Hoge, EA | 1 |
| Keshaviah, A | 1 |
| Stein, MB | 2 |
| Dalrymple, KL | 1 |
| Silberman, EK | 1 |
| Stein, M | 1 |
| Simon, N | 1 |
| Knijnik, DZ | 2 |
| Blanco, C | 3 |
| Salum, GA | 2 |
| Moraes, CU | 1 |
| Mombach, C | 1 |
| Almeida, E | 1 |
| Pereira, M | 1 |
| Strapasson, A | 1 |
| Manfro, GG | 2 |
| Eizirik, CL | 2 |
| Moraes, C | 1 |
| Hauck, S | 1 |
| Mombach, CK | 1 |
| Strapasson, AC | 1 |
| Carter, G | 1 |
| Tubaki, BR | 1 |
| Chandrashekar, CR | 1 |
| Sudhakar, D | 1 |
| Prabha, TN | 1 |
| Lavekar, GS | 1 |
| Kutty, BM | 1 |
| Davidson, JR | 9 |
| Foa, EB | 1 |
| Connor, KM | 3 |
| Churchill, LE | 1 |
| Schneier, FR | 2 |
| Schmidt, A | 1 |
| Blanco-Jerez, CR | 1 |
| Marshall, RD | 1 |
| Sánchez-Lacay, A | 1 |
| Liebowitz, MR | 2 |
| Seedat, S | 1 |
| Vaishnavi, S | 1 |
| Sheehan, DV | 1 |
| Sheehan, KH | 1 |
| Tupler, LA | 4 |
| Potts, NL | 3 |
| Auta, J | 1 |
| Romeo, E | 1 |
| Kozikowski, A | 1 |
| Ma, D | 1 |
| Costa, E | 1 |
| Guidotti, A | 1 |
| Potts, N | 1 |
| Richichi, E | 1 |
| Krishnan, R | 1 |
| Ford, SM | 2 |
| Smith, R | 1 |
| Wilson, WH | 1 |
| Jefferson, JW | 2 |
| de Carle, AJ | 1 |
| Pato, MT | 1 |
| Clarvit, SR | 1 |
| Sutherland, SM | 1 |
| Colket, JT | 2 |
| Smith, RD | 2 |
| Lazeyras, F | 1 |
| Charles, HC | 1 |
| Krishnan, KR | 1 |
| Miner, CM | 1 |
| Malik, ML | 1 |
| Book, SW | 1 |
| Ferrell, F | 1 |
| Otto, MW | 2 |
| Munjack, DJ | 1 |
| Baltazar, PL | 1 |
| Bohn, PB | 1 |
| Cabe, DD | 1 |
| Appleton, AA | 1 |
| Reiter, SR | 1 |
| Rosenbaum, JF | 7 |
| Cohen, LS | 2 |
| Sachs, GS | 2 |
| O'Neil, C | 1 |
| Asher, R | 1 |
| Meltzer-Brody, S | 1 |
| Ontiveros, A | 1 |
| Fontaine, R | 2 |
| Fava, M | 1 |
| MacLaughlin, RA | 1 |
| Tesar, GE | 4 |
| Hirsch, M | 1 |
| Gastfriend, DR | 1 |
| Rosenblat, H | 1 |
| Herman, JB | 1 |
| Spier, SA | 2 |
| Woods, SW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving Outcomes in Pharmacotherapy of Social Phobia[NCT00282828] | Phase 4 | 397 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| The Role of Orexin in Human Panic Disorder[NCT02593682] | Phase 4 | 3 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Liebowitz Social Anxiety Scale (LSAS) is a 24-item scale assessing fear and avoidance in social and performance situations; it is widely used in studies of pharmacological treatment of Generalized Social Anxiety Disorder (GSAD). We analyzed the overall change in LSAS (last Phase II LSAS minus Week 10 LSAS). Higher numbers reflect greater drops in social anxiety disorder severity. Scores on the LSAS range from 0 to 144, with higher scores indicating greater pathology. (NCT00282828)
Timeframe: Change from Week 10 to Week 22
| Intervention | units on a scale (Mean) |
|---|---|
| Sertraline and Clonazepam | 27 |
| Venlafaxine | 18 |
| Sertraline and Placebo | 16 |
The Liebowitz Social Anxiety Scale (LSAS) is a 24-item scale assessing fear and avoidance in social and performance situations; it is widely used in studies of pharmacological treatment of Generalized Social Anxiety Disorder (GSAD). Scores on the LSAS range from 0 to 144, with higher scores indicating greater pathology. (NCT00282828)
Timeframe: Measured at Week 22 (Endpoint)
| Intervention | participants (Number) |
|---|---|
| Sertraline and Clonazepam | 17 |
| Venlafaxine | 11 |
| Sertraline and Placebo | 10 |
5 reviews available for clonazepam and Phobic Disorders
| Article | Year |
|---|---|
Pharmacological treatment of social anxiety disorder: a meta-analysis.
Topics: Acetates; Amines; Anti-Anxiety Agents; Antidepressive Agents; Antimanic Agents; Anxiety Disorders; C | 2003 |
Pharmacotherapy of social anxiety disorder: what does the evidence tell us?
Topics: Clonazepam; Comorbidity; Drug Therapy, Combination; Humans; Paroxetine; Phobic Disorders; Psychotrop | 2006 |
Treatment of social phobia with benzodiazepines.
Topics: Alprazolam; Benzodiazepines; Clinical Trials as Topic; Clonazepam; Double-Blind Method; Humans; Phob | 1994 |
Social phobia: everyone's disorder?
Topics: Adrenergic beta-Antagonists; Blushing; Clinical Trials as Topic; Clonazepam; Fluoxetine; Humans; Mon | 1996 |
Cognitive-behavioral therapy for social anxiety disorder: model, methods, and outcome.
Topics: Clinical Trials as Topic; Clonazepam; Cognitive Behavioral Therapy; Combined Modality Therapy; Human | 1999 |
11 trials available for clonazepam and Phobic Disorders
| Article | Year |
|---|---|
A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Clonazepam; Cyclohexanols; Double-Blind Method; Drug Administration Sche | 2014 |
A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Clonazepam; Combined Modality Therapy; Female; Humans; Male; Middle Aged | 2008 |
Defense style changes with the addition of psychodynamic group therapy to clonazepam in social anxiety disorder.
Topics: Anticonvulsants; Clonazepam; Combined Modality Therapy; Defense Mechanisms; Diagnostic and Statistic | 2009 |
Clinical efficacy of Manasamitra Vataka (an Ayurveda medication) on generalized anxiety disorder with comorbid generalized social phobia: a randomized controlled study.
Topics: Adult; Anxiety; Anxiety Disorders; Bacopa; Biological Products; Clonazepam; Depression; Disorders of | 2012 |
Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 2004 |
Treatment of social phobia with clonazepam and placebo.
Topics: Adult; Anxiety; Clonazepam; Double-Blind Method; Female; Humans; Male; Phobic Disorders; Pilot Proje | 1993 |
A 2-year follow-up of social phobia. Status after a brief medication trial.
Topics: Adult; Clonazepam; Comorbidity; Double-Blind Method; Female; Follow-Up Studies; Health Status; Human | 1996 |
A repeat proton magnetic resonance spectroscopy study in social phobia.
Topics: Adult; Aspartic Acid; Cerebral Cortex; Choline; Clonazepam; Creatine; Female; GABA Modulators; Human | 1997 |
Discontinuation of clonazepam in the treatment of social phobia.
Topics: Adult; Anticonvulsants; Clonazepam; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 1998 |
Clonazepam in the treatment of social phobia: a pilot study.
Topics: Adult; Aged; Clonazepam; Female; Humans; Male; Middle Aged; Personality Inventory; Phobic Disorders; | 1990 |
Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder.
Topics: Adult; Agoraphobia; Alprazolam; Clinical Trials as Topic; Clonazepam; Dehydroepiandrosterone; Double | 1989 |
25 other studies available for clonazepam and Phobic Disorders
| Article | Year |
|---|---|
A Tale of COVID-19: Beyond Physical Ailment.
Topics: Anxiety; Anxiety Disorders; Child; Clonazepam; Cognitive Behavioral Therapy; COVID-19; Diagnosis, Di | 2021 |
Treatment in nonresponsive patients with social anxiety: back to the future with benzodiazepines.
Topics: Anti-Anxiety Agents; Clonazepam; Cyclohexanols; Female; Humans; Male; Phobic Disorders; Sertraline; | 2014 |
Longer term outcomes need to be examined for enhancing the treatment of social anxiety disorder after insufficient improvement with sertraline.
Topics: Anti-Anxiety Agents; Clonazepam; Cyclohexanols; Female; Humans; Male; Phobic Disorders; Sertraline | 2014 |
The role of benzodiazepines in treating social anxiety disorder.
Topics: Anti-Anxiety Agents; Clonazepam; Cyclohexanols; Female; Humans; Male; Phobic Disorders; Sertraline | 2014 |
Response to Silberman.
Topics: Anti-Anxiety Agents; Clonazepam; Cyclohexanols; Female; Humans; Male; Phobic Disorders; Sertraline | 2014 |
Animal behavior case of the month. Hyperactivity.
Topics: Animals; Anti-Anxiety Agents; Behavior Therapy; Behavior, Animal; Clonazepam; Dogs; Male; Methylphen | 2011 |
Hyperhidrosis in social anxiety disorder.
Topics: Acetates; Adult; Amines; Calcium Channel Blockers; Clinical Trials as Topic; Clonazepam; Cognitive B | 2002 |
Perceived stress in anxiety disorders and the general population: a study of the Sheehan stress vulnerability scale.
Topics: Adult; Anti-Anxiety Agents; Clinical Trials as Topic; Clonazepam; Cross-Sectional Studies; Female; F | 2007 |
Comorbid social phobia: pharmacologic strategies.
Topics: Clinical Trials as Topic; Clonazepam; Comorbidity; Humans; Mental Disorders; Monoamine Oxidase Inhib | 1995 |
Practical approaches to the treatment of social phobia.
Topics: Adrenergic beta-Antagonists; Behavior Therapy; Benzamides; Benzodiazepines; Bupropion; Clonazepam; C | 1994 |
Social phobia: an overview of treatment strategies.
Topics: Adrenergic beta-Antagonists; Clonazepam; Cognitive Behavioral Therapy; Humans; Monoamine Oxidase Inh | 1993 |
Participation of mitochondrial diazepam binding inhibitor receptors in the anticonflict, antineophobic and anticonvulsant action of 2-aryl-3-indoleacetamide and imidazopyridine derivatives.
Topics: Aggression; Allosteric Regulation; Animals; Anti-Anxiety Agents; Anticonvulsants; Behavior, Animal; | 1993 |
Social phobia and stuttering.
Topics: Anxiety Disorders; Clonazepam; Combined Modality Therapy; Humans; Male; Middle Aged; Phobic Disorder | 1996 |
The offensive subtype of Taijin-kyofu-sho in New York City: the phenomenology and treatment of a social anxiety disorder.
Topics: Adolescent; Adult; Anxiety Disorders; Benzamides; Clonazepam; Culture; Diagnosis, Differential; Ethn | 1996 |
Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder).
Topics: Acetates; Alprazolam; Amines; Anticonvulsants; Benzodiazepines; Clinical Trials as Topic; Clonazepam | 2001 |
Long-term treatment of social phobia with clonazepam.
Topics: Adult; Ambulatory Care; Attitude to Health; Clonazepam; Drug Administration Schedule; Female; Follow | 1991 |
Clonazepam for the treatment of social phobia.
Topics: Adolescent; Adult; Anxiety Disorders; Clonazepam; Comorbidity; Drug Administration Schedule; Female; | 1990 |
Longitudinal course of panic disorder: findings from the Massachusetts General Hospital Naturalistic Study.
Topics: Alprazolam; Anxiety Disorders; Child, Preschool; Chronic Disease; Clonazepam; Cognitive Behavioral T | 1990 |
Social phobia and clonazepam.
Topics: Adult; Arousal; Clonazepam; Female; Humans; Male; Middle Aged; Phobic Disorders | 1990 |
Adjunctive buspirone in benzodiazepine treatment of four patients with panic disorder.
Topics: Adult; Alprazolam; Anti-Anxiety Agents; Anxiety; Buspirone; Clonazepam; Diazepam; Drug Combinations; | 1989 |
Panic attacks triggered by photic stimulation.
Topics: Adult; Clonazepam; Fear; Female; Humans; Panic; Phobic Disorders; Photic Stimulation | 1989 |
Clonazepam in the treatment of panic disorder and agoraphobia.
Topics: Adult; Aged; Agoraphobia; Alprazolam; Carbon Dioxide; Clonazepam; Fear; Female; Humans; Male; Middle | 1987 |
Treatment of panic disorder and agoraphobia with clonazepam.
Topics: Adolescent; Adult; Aged; Agoraphobia; Alprazolam; Anxiety Disorders; Benzodiazepines; Benzodiazepino | 1986 |
Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up.
Topics: Adolescent; Adult; Aged; Agoraphobia; Anxiety Disorders; Clonazepam; Fear; Female; Follow-Up Studies | 1986 |
Clonazepam for panic disorders and agitation.
Topics: Adult; Agoraphobia; Benzodiazepinones; Clonazepam; Fear; Female; Humans; Male; Panic; Phobic Disorde | 1985 |